Published in Cancer Weekly, July 18th, 2000
"Previous studies in the woodchuck model of HBV infection have demonstrated that the nucleoside analogue, L-FMAU, had potent antiviral activity," said J. Gerin and colleagues from the Georgetown University Medical Center, Maryland, and Cornell University, New York. "Treatment of chronic carriers had a profound effect on levels of virus and surface antigen (WHsAg) with continued suppression of these markers following drug withdrawal.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.